DOI: 10.1002/cnr2.2068 ISSN: 2573-8348

Effect of 2‐methoxyestradiol on mammary tumor initiation and progression

Kimberly T. Peta, Chrisna Durandt, Marlene B. van Heerden, Anna M. Joubert, Michael S. Pepper, Melvin A. Ambele
  • Cancer Research
  • Oncology

Abstract

Background

The anti‐cancer agent 2‐methoxyestradiol (2‐ME) has been shown to have anti‐proliferative and anti‐angiogenic properties. Previously, the effect of 2‐ME on early‐ and late‐stage breast cancer (BC) was investigated in vivo using a transgenic mouse model (FVB/N‐Tg(MMTV‐PyVT)) of spontaneous mammary carcinoma. Anti‐tumor effects were observed in late‐stage BC with no effect on early‐stage BC. Given the contrasting results obtained from the different BC stages, we have now investigated the effect of 2‐ME when administered before the appearance of palpable tumors.

Methods

Each mouse received 100 mg/kg 2‐ME on day 30 after birth, twice per week for 28 days, while control mice received vehicle only. Animals were terminated on day 59. Lung and mammary tissue were obtained for immunohistochemical analysis of CD163 and CD3 expression, and histological examination was performed to analyze tumor necrosis. Additionally, blood samples were collected to measure plasma cytokine levels.

Results

2‐ME increased tumor mass when compared to the untreated animals (p = .0139). The pro‐tumorigenic activity of 2‐ME was accompanied by lower CD3+ T‐cell numbers in the tumor microenvironment (TME) and high levels of the pro‐inflammatory cytokine interleukin (IL)‐1β. Conversely, 2‐ME‐treatment resulted in fewer CD163+ cells detectable in the TME, increased levels of tumor necrosis, increased IL‐10 plasma levels, and low IL‐6 and IL‐27 plasma levels.

Conclusion

Taken together, these findings suggest that 2‐ME promotes early‐stage BC development.

More from our Archive